Given the ability of the AR-F876L mutant to mediate enzalutamide resistance by causing enzalutamide to function as an agonist, we first determined whether these inhibitor-refractory cancer cells would be vulnerable to protein degradation. The gene discussed is AR; the disease is cancer.